Impact of duloxetine on male fertility: A randomised controlled clinical trial.
DNA fragmentation
SNRIs
duloxetine
semen parameters
Journal
Andrologia
ISSN: 1439-0272
Titre abrégé: Andrologia
Pays: Germany
ID NLM: 0423506
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
revised:
15
07
2021
received:
10
06
2021
accepted:
26
07
2021
pubmed:
11
8
2021
medline:
6
10
2021
entrez:
10
8
2021
Statut:
ppublish
Résumé
This study assessed the impact of duloxetine (serotonin and norepinephrine reuptake inhibitor) on semen parameters, sperm DNA fragmentation and serum hormones. We performed a double-blind, placebo-controlled, randomised clinical trial of duloxetine 60mg or placebo daily for 6 weeks (5 weeks full dose and 1 week taper). The primary outcome was the proportion of men with abnormal DNA fragmentation during and after duloxetine administration. Secondary outcomes were changes in semen parameters and hormones on treatment (2 and 6 weeks) and after discontinuation (8 and 10 weeks). Sixty-eight healthy males aged 18-65 were included. Duloxetine was not associated with an increase in the proportion of participants with abnormal sperm DNA fragmentation terminal deoxynucleotidyl transferase dUTP nick-end labelling scores (>25%) on treatment (p = 0.09) or after treatment (p = 0.56), nor did median sperm DNA fragmentation increase on treatment. Compared with placebo, there were no changes in bulk semen parameters during treatment. Limited changes in hormonal values were detected. This first published human study of a serotonin and norepinephrine reuptake inhibitor on male fertility revealed no clinically meaningful effects on sperm DNA fragmentation, semen parameters or serum hormones. Duloxetine, and possibly other serotonin and norepinephrine reuptake inhibitors, may be considered for men desiring fertility who require antidepressant treatment.
Identifiants
pubmed: 34374108
doi: 10.1111/and.14207
pmc: PMC8487983
mid: NIHMS1728583
doi:
Substances chimiques
Antidepressive Agents
0
Serotonin Uptake Inhibitors
0
Duloxetine Hydrochloride
9044SC542W
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14207Subventions
Organisme : NICHD NIH HHS
ID : P50 HD076210
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002384
Pays : United States
Organisme : NP, CK, RF, and PB were supported in part by the Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust.
Organisme : Funding provided by Weill Cornell Medical College Clinical & Translational Science Center (NIH/NCATS UL1TR002384).
Informations de copyright
© 2021 Wiley-VCH GmbH.
Références
Int J Impot Res. 2011 Nov-Dec;23(6):257-61
pubmed: 21776003
CNS Drugs. 2007;21(7):581-609
pubmed: 17579500
Nat Rev Urol. 2015 Jul;12(7):373-82
pubmed: 26057063
Int J Urol. 2020 Jan;27(1):39-46
pubmed: 31542895
J Clin Psychopharmacol. 2016 Dec;36(6):658-668
pubmed: 27753729
Prim Care Companion J Clin Psychiatry. 2001 Feb;3(1):22-27
pubmed: 15014625
J Biol Chem. 1992 Oct 15;267(29):20820-5
pubmed: 1400397
Free Radic Biol Med. 1998 Nov 1;25(7):803-17
pubmed: 9823546
Int J Reprod Biomed. 2018 Jun;16(6):365-372
pubmed: 30123864
Br J Urol. 1980 Jun;52(3):226-8
pubmed: 7426983
CNS Spectr. 2005 Sep;10(9):732-47
pubmed: 16142213
Best Pract Res Clin Obstet Gynaecol. 2003 Apr;17(2):211-29
pubmed: 12758096
J Clin Psychiatry. 2000;61 Suppl 11:9-17
pubmed: 10926050
Bioorg Med Chem Lett. 2006 May 1;16(9):2509-12
pubmed: 16464584
J Clin Psychopharmacol. 1998 Aug;18(4):274-81
pubmed: 9690692
Psychiatry (Edgmont). 2007 Dec;4(12):25-8
pubmed: 20436760
Fertil Steril. 2010 Aug;94(3):1021-6
pubmed: 19515367
Fertil Steril. 1981 Oct;36(4):503-6
pubmed: 6793407
Drugs Context. 2015 Oct 08;4:212290
pubmed: 26576188
J Urol. 2008 Nov;180(5):2124-8
pubmed: 18804223
J Clin Pharm Ther. 2010 Apr;35(2):177-88
pubmed: 20456736
Drug Healthc Patient Saf. 2010;2:141-50
pubmed: 21701626
NCHS Data Brief. 2020 Sep;(377):1-8
pubmed: 33054926
Urology. 2007 Jan;69(1):185.e5-7
pubmed: 17270655